Pregabalin Attenuates Excitotoxicity in Diabetes

Chin-Wei Huang1*, Ming-Chi Lai2, Juei-Tang Cheng3, Jing-Jane Tsai1, Chao-Ching Huang4, Sheng-Nan Wu5*

1 Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 2 Department of Pediatrics, Chi-Mei Foundation Medical Center, Tainan City, Taiwan, 3 Department of Pharmacology, National Cheng Kung University, Tainan, Taiwan, 4 Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan, 5 Department of Physiology, National Cheng Kung University, Tainan, Taiwan

Abstract

Diabetes can exacerbate seizures and worsen seizure-related brain damage. In the present study, we aimed to determine whether the standard antiepileptic drug pregabalin (PGB) protects against pilocarpine-induced seizures and excitotoxicity in diabetes. Adult male Sprague-Dawley rats were divided into either a streptozotocin (STZ)-induced diabetes group or a normal saline (NS) group. Both groups were further divided into subgroups that were treated intravenously with either PGB (15 mg/kg) or a vehicle; all groups were treated with subcutaneous pilocarpine (60 mg/kg) to induce seizures. To evaluate spontaneous recurrent seizures (SRS), PGB-pretreated rats were fed rat chow containing oral PGB (450 mg) for 28 consecutive days; vehicle-pretreated rats were fed regular chow. SRS frequency was monitored for 2 weeks from post-status epilepticus day 15. We evaluated both acute neuronal loss and chronic mossy fiber sprouting in the CA3 area. In addition, we performed patch clamp recordings to study evoked excitatory postsynaptic currents (eEPSCs) in hippocampal CA1 neurons for both vehicle-pretreated rats with SRS. Finally, we used an RNA interference knockdown method for Kir6.2 in a hippocampal cell line to evaluate PGB’s effects in the presence of high-dose ATP. We found that compared to vehicle-pretreated rats, PGB-treated rats showed less severe acute seizure activity, reduced acute neuronal loss, and chronic mossy fiber sprouting. In the vehicle-treated STZ rats, eEPSC amplitude was significantly lower after PGB administration, but glibenclamide reversed this effect. The RNA interference study confirmed that PGB could counteract the ATP-sensitive potassium channel (KATP)-closing effect of high-dose ATP. By opening KATP, PGB protects against neuronal excitotoxicity, and is therefore a potential antiepileptogenic in diabetes. These findings might help develop a clinical algorithm for treating patients with epilepsy and comorbid metabolic disorders.

Introduction

In modern societies, more than one-third of the adult population develops metabolic syndrome (MS) [1]. Due to its major role in MS, diabetes and its complications deserve attention [2]. Both clinical and laboratory studies [3–5] report that MS and diabetes increase seizure severity, which can significantly affect neurological outcome. We showed previously that diabetes worsened seizure-induced brain damage and impaired both cognition and synaptic plasticity [6].

Using in vitro hippocampal neurons, we demonstrated that ATP-sensitive potassium channel (KATP) agonists could hyperpolarize membrane potentials and attenuate action potential firing when extracellular glucose concentrations are high [7]. The KATP contains pore-forming units with inward rectifying characteristics (Kir6.1 or Kir6.2) and sulfonylurea (SUR) binding sites (SUR1, SUR2A, or SUR2B) [8]. Kir6.2 mRNA is found in cells distributed throughout the brain [9] and overlaps considerably with SUR1 mRNA. These observations indicate the Kir6.2/SUR1 complex is an ideal candidate for studying KATP function in the brain [10,11].

We previously [12] found that the use of diazoxide to open KATP could help reduce seizure severity and protect against seizure-induced hippocampal damage in diabetes. However, alteration of KATP function in diabetes has been reported [14]. Furthermore, it is uncertain whether the KATP agonist diazoxide can affect blood glucose levels [13]. In this study, we aimed to determine whether standard antiepileptic drugs (AEDs) could benefit seizure activity in diabetes by opening KATP in vivo. Pregabalin (PGB, S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid), a standard AED, is more effective in controlling seizures [15] than its analogue gabapentin [16]. It is well established that PGB can relieve diabetic neuropathic pain and anxiety disorder [17,18]. PGB modulates neuronal excitability by binding with the alpha-2-delta subunit of P/Q-type calcium channels [19]. We previously identified a unique mechanism in which PGB opened KATP in hippocampal neurons in vitro by modulating the probability of KATP opening, but not unitary conductance [20]. Whether this observation is relevant to in vivo studies of diabetes, however, remains unknown.

Patients with epilepsy must carefully monitor their blood glucose levels to attenuate seizure severity. Attenuation of seizure severity could subsequently help prevent long-term metabolic and...
V injections were given 20 min before the pilocarpine injection. To further divide the groups into subgroups that were given either PGB (15 mg/kg; i.v.) or NS + PGB or a vehicle (V) containing NS and dimethyl sulfoxide (DMSO; NS:DMSO, 1:3; i.v.) in a volume equal to the PGB dose (STZ+V, NS+V). PGB and V injections were given 20 min before the pilocarpine injection.

In Vivo experiments

Grouping. On day 1, the rats were divided into the following 2 groups: the streptozotocin (STZ) group, which was injected intravenously (i.v.) with 70 mg/kg of STZ to induce diabetes, and a control group injected (i.v.) with normal saline (NS) (Fig. 1). On day 10, status epilepticus was induced in both groups by subcutaneously (s.c.) injecting lithium chloride, and then 18–20 h later by injecting (s.c.) pilocarpine. We injected the rats with methylscopolamine 30 min before the pilocarpine injection to reduce the peripheral consequences of pilocarpine [12]. To evaluate the effect of PGB on pilocarpine-induced seizures and excitotoxicity, we gave STZ+PGB and NS+PGB rats PGB (450 mg/day) in their regular daily chow for 28 consecutive days, beginning 24 h after status epilepticus. STZ+V and NS+V rats were given regular chow during this 28-day period.

Materials and Methods

Experiments were conducted in accordance with the guidelines of the Experimental Ethics Committee of National Cheng Kung University. Procedures for animal experimentation were reviewed and approved by the Institutional Animal Care and Use Committee.

Animals

Adult male Sprague-Dawley rats weighing 180–200 g were purchased from National Cheng Kung University. Rats were housed in the university’s Animal Center and allowed free access to water and a pelleted rodent diet (Richmond Standard; PMI Feeds, St. Louis, MO). Efforts were made to reduce the number of rats used.

Figure 1. Experimental protocol. Pilocarpine (60 mg/kg; s.c.) was administered to induce seizures on day 10 (n = 30 in each group). Lithium chloride (3 meq/kg; i.p.) and methylscopolamine (25 mg/kg; s.c.) were injected 18–20 h and 30 min before the pilocarpine injection, respectively [12]. Twenty-four hours after pilocarpine-induced status epilepticus (day 11), acute pathological study on neuronal loss was performed (n = 5 in each group). Twenty-eight days after status epilepticus (day 39), chronic pathological study on mossy fiber sprouting was performed (n = 5 in each group).

doi:10.1371/journal.pone.0065154.g001

vascular complications resulting from AED therapy [21]. Both traditional and some newer AEDs, including phenytoin, carbamazepine, valproic acid, and topiramate, can affect blood glucose stability [23–26]. Unlike other AEDs, PGB shows no obvious effects on blood glucose levels [22]. Thus, we aimed to determine whether PGB has a distinct effect on pilocarpine-induced neuronal excitotoxicity in diabetes.

To evaluate the effect of PGB on chronic pilocarpine-induced seizures and excitotoxicity, we gave STZ+PGB and NS+PGB rats PGB (450 mg/day) in their regular daily chow for 28 consecutive days, beginning 24 h after status epilepticus. STZ+V and NS+V rats were given regular chow during this 28-day period.

Measuring glucose concentrations. Plasma glucose concentration was measured in all rats on day 10, before status epilepticus was induced. We measured plasma glucose concentration by snipping each rat’s tail and collecting a small blood sample (~5 μL) on a test strip (Optium blood glucose electrode; Abbott Diabetes Care Inc., USA) that was inserted into a glucose meter (MediSense Optium Xceed, Abbott). The glucose level reading was available in 20 s and was measured in milligrams per deciliter (mg/dL). Rats in the STZ group with fasting blood glucose levels lower than 126 mg/dL were excluded from the study [6]. We again measured plasma glucose concentration 15 min after PGB or V injections (before pilocarpine-induced seizures) to determine the effect of PGB treatment on plasma glucose concentration. The final plasma glucose measurement was performed on day 28 to determine the effect of chronic PGB treatment on plasma glucose concentration.

Lithium-pilocarpine seizure modeling. On day 10, all rats were injected with lithium chloride (3 meq/kg; i.p.) and methylscopolamine (25 mg/kg; s.c.), before seizures were induced with pilocarpine injections (60 mg/kg; s.c.). All rats demonstrated behavioral characteristics during epileptic seizures that were similar to those reported previously [6,27,28]. Mouth and facial movements, head bobbing and nodding, scratching, masticatory automatisms, and exploratory behavior were observed within 15 to 20 min (stages 1–2). Myoclonic movements of the head and forelimbs (stage 3) began within 20 to 25 min, and progressed to status epilepticus (stages 4–5), with rearing and falling, approximately 50 min after pilocarpine injection. Diazepam (5 mg/kg, i.p.) was administered to reduce seizure activity if status epilepticus lasted for 90 min [29]. We determined the seizure onset latency by measuring the time interval between pilocarpine injection and the onset of overt seizure behaviors (stage 3). The rats were monitored for 24 h following status epilepticus, and supportive care was implemented, including body temperature maintenance, feeding,
and adequate hydration. Status epilepticus-related mortality was calculated during the first 24 h after onset.

For chronic evaluation, we began monitoring seizure frequency 14 days after status epilepticus. Rats were monitored with a video camera mounted above the cage for 4 h per day, over 14 consecutive days. A trained technician blinded to the experimental design examined the videos for seizure behavior (i.e., running, jumping, rearing, lordosis, and erect tail). When seizure-like activity was observed, the video was reviewed to confirm seizure

Figure 2. Pilocarpine-induced seizures in the streptozotocin (STZ)-induced diabetes and normal saline (NS) groups. A: The STZ+PGB (pregabalin) group had a significantly lower percentage of severe seizures (stages 3–5) than did the STZ+V (vehicle) group (p < 0.01). Similarly, the NS+PGB group had a lower percentage of severe seizures than the NS+V group did (p < 0.05). B: Status epilepticus-related mortality was significantly higher in the STZ+V group than in the STZ+PGB group (p < 0.05, n = 30 in each group). C: There were significantly fewer spontaneous recurrent seizures (mean daily seizures) in the PGB groups than in the non-PGB groups (STZ+V = 1.6; STZ+PGB = 0.6; NS+V = 1.5; NS+PGB = 0.7) (χ² test, Fisher’s exact test and unpaired t-test, n = 10–13 in each group, **p < 0.01; *p < 0.05). doi:10.1371/journal.pone.0065154.g002

For chronic evaluation, we began monitoring seizure frequency 14 days after status epilepticus. Rats were monitored with a video camera mounted above the cage for 4 h per day, over 14 consecutive days. A trained technician blinded to the experimental design examined the videos for seizure behavior (i.e., running, jumping, rearing, lordosis, and erect tail). When seizure-like activity was observed, the video was reviewed to confirm seizure

Figure 3. Neuronal loss during the post-status epilepticus acute stage. Twenty-four hours after status epilepticus, cresyl violet staining showed substantially fewer neurons in the hippocampal CA3 area in A, the STZ+V group, than in B, the STZ+PGB group. There was more neuronal death in the hippocampal CA3 area in C, the NS+V group, than in D, the NS+PGB group. A semi-quantitative analysis, E, showed that the difference between the CA3 areas was significant (STZ+V versus STZ+PGB, p < 0.01; NS+V versus NS+PGB, p < 0.05) (Kruskal-Wallis H test and then Dunn’s multiple comparison test, n = 5 in each group, **p < 0.01; *p < 0.05). The scale bar (D) represents 40 μM. doi:10.1371/journal.pone.0065154.g003
behaviors.

Histopathology

Acute stage: cresyl violet staining. Twenty-four hours after status epilepticus, the rats were anesthetized with an overdose of pentothal (60 mg/kg; i.p., n = 5 in each group), and their brains were removed and stored at −80°C. Coronal sections (20-μm thick) of the hippocampus were fixed in formaldehyde for cresyl violet staining as previously described [30]. The cresyl violet-stained sections were examined for gross indications of hippocampal damage. Cells were counted in Nissl-stained sections (10-μm thick) that were magnified (×400) using a computerized image analysis system (Image Plus 2.0; Motic, Richmond, British Columbia, Canada). The hippocampal subfields were defined by an imaginary line connecting the tips of the granule cell layer blades, which separated the cornu ammonis (CA) 3c (medially) from CA3b (laterally), and CA2 from CA1 (Huang et al., 2009). The severity of neuronal damage in the different hippocampus subfields was scored semi-quantitatively by using the following scale: 0 = no damage; 1 = less than 10% neuron loss; 2 = between 11% and 50% neuron loss; and 3 = greater than or equal to 50% neuron loss [31]. An investigator blind to the study design determined these values for the different groups. The mean values for each group were also determined.

Chronic stage: Timm’s staining. The brains were removed 28 days after status epilepticus, and coronal sections were cut (20-μm thick) through the entire hippocampus on a freezing microtome. Every sixth section was stained using Timm’s stain [32]. The sections were developed in the dark for 10–45 min in 200 ml of a solution containing citric acid (5.1 g), sodium citrate (4.7 g), hydroquinone (3.47 g), AgNO3 (212.25 mg), and 120 ml of 50% Arabic gum. Timm’s staining was assessed from the septal area to the temporal hippocampus (the region extending from 2.8 to 3.8 mm posterior to the bregma). We used a semi-quantitative scale to evaluate the extent of mossy fiber sprouting in the pyramidal and infrapyramidal areas of the hippocampal CA3 region, and the granular cell and inner molecular layers of the dentate gyrus [30]. The scoring criteria were as follows: 0 = no granules, 1 = occasional discrete granule bundles, 2 = occasional-to-moderate granules, 3 = prominent granules, 4 = prominent near-continuous granule band, and 5 = continuous or nearly continuous dense granule band.

Western blotting of Kir6.2 protein expression

Twenty-eight days after status epilepticus, the brains of the rats with chronic seizures were removed. The hippocampus was

Figure 4. Mossy fiber sprouting in the post-status epilepticus chronic stage. There were more prominently Timm’s-stained fibers in the hippocampal CA3 area in A, the STZ+V group (strata pyramidale and oriens; arrow), than in B, the STZ+PGB group. There were also more Timm’s-stained fibers in C, the NS+V group (strata pyramidale and oriens; arrow), than in D, the NS+PGB group. E: The Timm’s score for the quantitative analysis of mossy fiber sprouting in the CA3 region was significantly higher in the STZ+V and NS+V groups than in the other two groups (STZ+V versus STZ+PGB, *p<0.01; NS+V versus NS+PGB, *p<0.05) (ANOVA, n = 5 in each group). The scale bar (D) represents 40 μM. doi:10.1371/journal.pone.0065154.g004

Figure 5. Representative Western blots showing Kir6.2 protein expression in the hippocampus in the NS+V and STZ+V groups. Immunoblots of 100 μg of tissue lysate from rats in the two groups against Kir6.2 antibody. (Unpaired t-test, n = 5 per group, *p<0.05). doi:10.1371/journal.pone.0065154.g005
dissected and put in an ice-cold homogenized buffer containing 10 mM Tris-HCl (pH 7.4), 20 mM EDTA, 10 mM EGTA, 20 mM b-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, and the protease inhibitors leupeptin (25 mg/ml) and aprotinin (25 mg/ml). The mixture was centrifuged at 1,000 g for 10 min at 4°C. The supernatant containing the membrane fraction was then centrifuged at 48,000 g for 30 min at 4°C. The supernatant was removed, and the pellet was resuspended on ice in Triton X-100 lysis buffer for 30 min, homogenized, and then centrifuged at 14,010 g for 20 min at 4°C. Finally, the supernatant was transferred to a new Eppendorf tube and stored at −20°C. The membrane extracts (20–80 mg) were separated using SDS-polyacrylamide gel electrophoresis, and the proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (BioTrace™; Pall Corporation, Pensacola, FL). After the proteins were blocked, Western blots were developed using antibodies for Kir6.2 (Santa Cruz Biotechnology, Santa Cruz, CA). The blots were subsequently hybridized using horseradish peroxidase-conjugated anti-goat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), and developed using a reagent (Western Lightning Chemiluminescence Reagent PLUS; PerkinElmer Life Sciences, Boston, MA). The blot was incubated with goat polyclonal antibody (1:1000) to bind the actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The immunoblots for Kir6.2 and actin were quantified using a laser densitometer.

**In vitro experiments**

**Preparing and maintaining hippocampal slices.** Twenty-eight days after status epilepticus, the rats in the STZ+V and NS+V groups were deeply anesthetized with ether and immediately decapitated. Their brains were removed and immersed in ice-cold artificial cerebrospinal fluid (ACSF). The ACSF consisted of 124 mM NaCl, 25 mM NaHCO3, 3 mM KCl, 1.24 mM KH2PO4, 1.4 mM MgSO4, 2.2 mM CaCl2, and 10 mM glucose, and was continuously aerated with 95% O2 and 5% CO2 (pH 7.4) at 4°C. Transverse hippocampal slices (400-μm thick) were prepared using a vibrating tissue slicer (DTK-100; Dosaka EM, Kyoto, Japan). The slices were then pre-incubated in ACSF for at least 1 h at 30°C. Slices from the STZ rats were maintained in 20 mM glucose. The NaCl concentration in the ACSF was adjusted to maintain an osmolarity of 280–290 mOsm.

**Slice electrophysiological recording.** Slices were transferred to a recording chamber, held in place with a nylon mesh, and perfused continuously (at a rate of 2–3 ml/min) with carbogenated ACSF containing bicuculline methiodide (10 μM) to block GABA A receptor-mediated inhibitory synaptic currents. eEPSCs were recorded at 32°C (pH = 7.2–7.3) from CA1 pyramidal neurons by using the patch-clamp technique in the whole-cell configuration. Recording pipettes were pulled from borosilicate glass capillaries with an inner filament on a pipette puller (P-2000; Sutter Instrument, Novato, CA). The pipettes (resistance range: 3–6 MΩ) were filled with a solution containing 132.5 mM Gs-gluconate, 17.5 mM CsCl, 2 mM MgCl2, 0.5 mM

---

**Figure 6. Glibenclamide reversed PGB’s effects on the evoked excitatory postsynaptic currents in hippocampal slices.** The evoked excitatory postsynaptic synaptic currents (eEPSCs) amplitude in CA1 neurons in the STZ+V and NS+V groups 28 days after status epilepticus. **A, B:** In the STZ+V group, PGB (25 μM) significantly reduced the eEPSC amplitude (55% ± 6% of baseline amplitude in STZ+V). This reduction was significantly reversed by glibenclamide (10 μM) (85% ± 6% of baseline amplitude in STZ+V); the reduction was non-significantly reversed by glibenclamide (84% ± 5% of baseline amplitude in NS+V) (ANOVA, n = 6–7 slices) (*p<0.05). doi:10.1371/journal.pone.0065154.g006
EGTA, 10 mM HEPES, 4 mM ATP, and 5 mM QX-314, with the pH adjusted to 7.2 by using CsOH. Excitatory postsynaptic responses were evoked by stimulating the Schaffer collateral-commissural pathway via a constant current pulse (0.05 ms) delivered through a tungsten bipolar electrode. Whole-cell recordings of CA1 neurons in brain slices were made using the “blind” method with an amplifier (MultiClamp 700A; Molecular Devices, Sunnyvale, CA).

A seal resistance of at least 1 GΩ and access resistance less than 20 MΩ that changed by less than 15% during a recording, were considered acceptable. Series resistance was optimally compensated. eEPSCs were recorded while CA1 neurons were voltage clamped at –60 mV. Inside-out configuration in patch clamp technology was used. The cells were maintained in flasks coated with 15 mg/mL of poly-l-lysine, and in Dulbecco’s modified Eagle’s medium that was adjusted with sodium bicarbonate (1.5 g/L), glucose (4.5 g/L), G418 (200 μg/mL), and puromycin (1 μg/mL), and supplemented with 10% fetal bovine serum. The cells were equilibrated in a humidified atmosphere of 5% CO2/95% O2 and a permissive air temperature of 34°C.

Small interfering RNA transfection

Custom stealth RNAi for rat Kir6.2 sense: 5’-AUAAUCUG-CACGAUCAGAAUAGGA-3’, antisense: 5’-UCCUUAU-UUGAUCUGGACGAU-3’ and scrambled negative control siRNA, which does not interfere with any known mRNA, were purchased from Invitrogen (Carlsbad, CA). H19-7 cells were transfected with siRNAs (25 nM) by using a transfection reagent (Lipofectamine RNAiMAX; Invitrogen, Carlsbad, CA) in accordance with the manufacturer’s protocol and as previously described [34,35]. Briefly, gene-specific siRNA oligomers were diluted in a reduced serum medium (Opti-MEM I; Invitrogen, Carlsbad, CA) and mixed with the transfection reagent. The complex was incubated at room temperature for 20 min and then added to the cells. Transfected cells were incubated at 34°C for 48 h before they were harvested. After incubation, the cells were
examined with patch-clamp recordings to evaluate channel function.

**Reverse transcriptase-polymerase chain reaction**

The RNAi knockdown efficiency of rat Kir6.2 mRNA in the H19-7 cells was determined using a semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA was extracted using a reagent (Trizol; Invitrogen, Carlsbad, CA) and reverse transcribed into cDNA by using reverse transcriptase (Superscript III; Invitrogen, Carlsbad, CA). The sequences of Kir6.2 primers used for PCR were [36]: 5'-GCAAGAGGCC- TAGAGAGCC-3' and 5'-GCCGCCATGTCCAGGTTGA-3'.

GADPH was the positive internal control. Rat Kir6.2 and GADPH mRNA were amplified using a reagent (PCR SuperMix; Invitrogen, Carlsbad, CA). PCR products were analyzed on 1.5% (w/v) agarose gel containing ethidium bromide and then visualized under ultraviolet light. Optical densities of DNA bands were scanned and quantified (Scion Image software; Scion, Frederick, MD).

**Cellular electrophysiological recording**

Immediately before each experiment, the cells were dissociated and an aliquot of cell suspension was transferred to a recording chamber mounted on the stage of an inverted microscope (DM-IL; Leica Microsystems, Wetzlar, Germany). The microscope was coupled to a digital video camera (DCR-TRV30; Sony, Japan) with a magnification of up to 1500× to monitor cell size during the experiments. The cells were immersed at room temperature (20–25°C) in normal Tyrode’s solution. The composition of normal Tyrode’s solution was 136.5 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 0.53 mM MgCl₂, 5.5 mM glucose, and 5.5 mM HEPES-NaOH buffer (pH 7.4). For single-channel recordings, the high K⁺ bathing solution contained 145 mM KCl, 0.53 mM MgCl₂, and 5 mM HEPES-KOH (pH 7.4); the pipette solution contained 145 mM KCl, 2 mM MgCl₂, and 5 mM HEPES-KOH (pH 7.2). Patch pipettes were pulled from borosilicate glass capillaries, and their diameters were ranging between 3 and 6 μM when immersed in normal Tyrode’s solution. Ion currents were measured in a whole-cell configuration. All potentials were corrected for liquid junction potential.

Single-channel currents from K<sub>ATP</sub> were analyzed using pCLAMP 9.0. Multi-Gaussian adjustments of the amplitude distributions between channels were used to determine unitary currents. The number of active channels in patch N was counted at the end of each experiment and used to normalize the opening probability at each potential. The opening probabilities were evaluated using an iterative process to minimize the χ² calculated with sufficient independent observations.

**Drugs and solutions**

STZ, lithium, scopolamine, glibenclamide, and pilocarpine were purchased from Sigma-Aldrich (St. Louis, MO) and PGB from Pfizer Pharmaceuticals. All other chemicals, unless otherwise noted, were locally purchased and of reagent grade.

**Statistical analysis**

Significance was set at p<0.05 for all statistical tests. The Shapiro-Wilk test was used to determine whether the data were normally distributed. Normally distributed continuous variables were assessed using t-tests or one-way analysis of variance (ANOVA), and then Fisher’s Least Significant Difference tests (SPSS 15.0; SPSS Institute, Chicago, IL). When the data were not normally distributed, analyses were performed with the non-parametric Kruskal-Wallis H test and Dunn’s multiple comparison tests. Analyses were performed using χ² tests, the Yates χ² test, or Fisher’s exact probability for nominal variables test. Continuous data are expressed as means ± standard error of the mean (SEM), unless otherwise indicated.

**Results**

PGB treatment did not affect blood glucose level in either the STZ or NS group

On day 10, blood glucose levels were significantly higher in STZ rats (352.1±17 mg/dL) than in NS rats (105.0±4 mg/dL, p<0.01). In addition, PGB did not affect plasma glucose levels in either PGB group (STZ+PGB = 357.4±12 mg/dL vs. STZ+V = 350.7±17 mg/dL; NS+PGB = 106±7 mg/dL vs. NS+V = 104±8 mg/dL, all p>0.1). Furthermore, chronic PGB treatment did not significantly affect plasma glucose levels. On day 28, the plasma glucose levels in each group were similar between STZ groups (STZ+PGB = 320.7±8 mg/dL vs. STZ+V = 321.4±6 mg/dL, all p>0.1) and between NS groups (NS+PGB = 98.8±6 mg/dL vs. NS+V = 99.4±5 mg/dL, all p>0.1).

PGB-treated rats had fewer severe acute seizures and less status epilepticus-related mortality

Compared to the STZ+V group, the STZ+PGB group showed significantly fewer severe acute seizures (stages 3–5) [STZ+PGB = 26.7% [8/30] vs. STZ+V = 83% [25/30], p<0.01] and lower status epilepticus-related mortality (STZ+PGB = 6.7% [2/30] vs. STZ+V = 46.7% [14/30], p<0.05) (Figs. 2–A, B). Compared to the NS+V group, the NS+PGB group had fewer severe seizures (NS+PGB = 13% [4/30] vs. NS+V = 56% [17/30], p<0.05), and lower status epilepticus-related mortality (NS+PGB = 6% [2/30] vs. NS+V = 40% [12/30], p<0.05) (Figs. 2-A, B). These findings suggest that PGB provides protection against seizures in diabetic hyperglycemia.

PGB-treated rats had fewer spontaneous recurrent seizures

After a latent phase of 2 weeks, most of the rats in STZ+V and NS+V groups had SRS (STZ+V = 91% [10/11], NS+V = 85% [11/13]), compared to STZ+PGB (50% [11/22]) and NS+PGB (48% [11/23]). The mean number of daily spontaneous seizures was quantified for each rat based on the daily 4-h monitoring period. The mean number of daily seizures was significantly smaller in the PGB groups than in the non-PGB groups (STZ+V = 1.6, STZ+PGB = 0.6, p<0.01; NS+V = 1.5, NS+PGB = 0.7, p<0.05) (Fig. 2C).

PGB-treated rats demonstrated less acute hippocampal damage after status epilepticus

Cresyl violet staining revealed fewer neurons in the hippocampal CA3 of the STZ+V rats (Fig. 3A) than in the STZ+PGB rats 24 h following status epilepticus (Fig. 3B). In addition, CA3 neuronal damage was more common in the NS+V rats (Fig. 3C) than in the NS+PGB rats (Figure 3D). A blind semi-quantitative analysis revealed that compared to the STZ+PGB rats, the STZ+V rats had significant hippocampal neuronal damage (STZ+V = 2.9±0.2; STZ+PGB = 2.1±0.1, p<0.01). The NS+V rats also showed more neuronal damage than the NS+PGB rats (NS+V = 2.5±0.3; NS+PGB = 2.0±0.3, p<0.05, Fig. 3E). There were no significant differences in cell counts in hippocampal CA1 areas, the hilus, and dentate granular cell layers between the
STZ+V and STZ+PGB rats or between the NS+V and NS+PGB rats.

PGB-treated rats demonstrated less mossy fiber sprouting

Timm’s staining (Figs. 4–A, B, E) revealed at 28 days after status epilepticus, the STZ+V rats showed greater dense mossy fiber sprouting in the hippocampal CA3 region than did the STZ+PGB rats (STZ+V = 4.1±0.3, STZ+PGB = 1.2±0.1, p<0.01). The NS+V group had a higher Timm’s score than the NS+PGB group (NS+V = 3.1±0.2, NS+PGB = 0.7±0.1, p<0.05) (Figs. 4–C, D, E).

Kir6.2 expression was decreased in chronically diabetic rats

We investigated Kir6.2 expression in chronically diabetic rats in order to quantify K_{ATP} activity. Western blotting revealed both Kir6.2 and K_{ATP} subunit protein expression in NS+V and STZ+V rats. Quantitative analysis showed that Kir6.2 protein expression was significantly higher in the NS+V group than in the STZ+V group (0.72±0.08 vs. 0.22±0.03, p<0.05) (Fig. 5).

Glibenclamide reversed PGB’s effects on CA1-evoked EPSCs in hippocampal slices

The CA3 region with its extensive recurrent collateral system, is thought to be a critical site of hippocampal integrity. It’s suggested in sharp wave–related population bursts, the coherent discharge of CA3 neurons causes spiking activities in CA1 pyramidal neurons [37]. It’s reasonably hypothesized that neuronal excitability at CA1 would be markedly altered in either STZ or NS group in pilocarpine-induced epilepsy, even without marked cell loss. In the STZ+V group, PGB addition significantly reduced eEPSC amplitude (55±6% of baseline, p<0.05), which could be reversed by adding glibenclamide (10 μM) (85±6% of baseline, p<0.05) (Figs. 6–A, B). In the NS+V group, PGB addition significantly reduced the eEPSC amplitude (78±4% of baseline, p<0.05), but glibenclamide could not reverse this effect (84±5% of baseline) (Figs. 6–C, D). These findings suggest that PGB significantly modulates neuronal excitability in CA1 neurons by opening K_{ATP} in diabetic hyperglycemia with pilocarpine-induced epilepsy.

PGB opened K_{ATP} in the presence of high ATP concentrations in hippocampal neuron-derived H19-7 cells

We used RNAi for Kir6.2 in *in vitro* hippocampal neurons to further examine the protective role of PGB in diabetic hyperglycemia. A hippocampal neuron-derived H19-7 neuronal cell line stably expressing Kir 6.2 and the SUR1 subunit was transfected with siRNAs targeting Kir 6.2. The effects of RNAi were monitored at the mRNA and functional levels. RT-PCR revealed a significant reduction of Kir6.2 mRNA after RNAi (data not shown). The single-channel unitary conductance of the K_{ATP} in the H19-7 neurons was 76±1.8 pS at hyperpolarized potentials, with a reversal potential of 64.6±2.7 mV, which is consistent with inward rectification in K_{ATP}.

Using the inside-out configuration with patch clamp recordings, we found control neurons showed more channel activity (0.174±0.043) than the neurons with RNAi Kir6.2 knockdown (0.013±0.002) (Figs. 7–A, C). The addition of PGB (50 μM) significantly increased channel activity (0.399±0.068) in the control neurons, but not in the neurons with Kir6.2 knockdown (0.014±0.001; Figs. 7–A, C). The presence of ATP (1 mM) significantly attenuated channel activity in the control neurons (0.061±0.025) (Fig. 7B), but addition of PGB (50 μM) to ATP (1 mM) revealed significantly increased channel activity in control neurons (0.365±0.041) (Figs. 7–B, E). In the control neurons, the difference in opening probabilities between neurons treated with PGB+ATP or ATP alone was significantly greater (p<0.01) than that observed between the neurons treated with PGB alone and control neurons (p<0.05) (Figs. 7D–F).

Discussion

We examined whether PGB, a standard AED with K_{ATP} antagonist properties, protected diabetic rats against pilocarpine-induced seizures and excitotoxicity. We found that PGB (1) reduced acute seizure severity and status epilepticus-related mortality, (2) reduced chronic seizure frequency, (3) ameliorated neuronal damage induced by pilocarpine-induced epilepsy and hyperexcitability (these effects were attenuated by a K_{ATP} antagonist), and (4) positively opened K_{ATP} in the presence of a high concentration of ATP. We showed *in vivo* and *in vitro* evidence that PGB protected diabetic rats against hippocampal damage and seizures in a pilocarpine model, and that K_{ATP} opening effects were the underlying mechanism.

Modulated K_{ATP} may alter seizure thresholds and epileptiform activity, both *in vitro* and *in vivo* [38–40]. K_{ATP} activation leads to membrane potential hyperpolarization, which further protects neurons by reducing excitotoxicity in pilocarpine-induced status epilepticus [41] or hypoxia [42]. In this study, we showed that, hippocampal Kir6.2 expression is reduced in diabetic rats. This reduction could potentially lead to increased neuronal excitability. Interestingly, in spite of the reduced protein expression, PGB may activate the remaining Kir6.2 and induce neuroprotection. We showed previously [6] that diabetic rats in a pilocarpine-induced seizure model had more severe seizures and neuronal loss than controls, which further indicates diabetic (glucose) neuronal hyperexcitability. We thus hypothesized that, for seizures in patients with diabetes, targeting K_{ATP} will have some benefits in addition to those provided by other AEDs that do not open K_{ATP}.

Diazoxide, a well-known K_{ATP} agonist, reduces glutamate release by opening presynaptic K_{ATP} Kir6.2/SUR1 channels [43] and protects diabetic rats from status epilepticus-induced neuronal damage [12]. However, its effect on rats without diabetes was not significant. Compared with diazoxide, PGB had a protective effect, both in control rats and in diabetic rats, but with a more significant effect on the latter. The prominent K_{ATP} modulating effects, in addition to PGB’s calcium channel-modulating effects [44], suggest a possible synergistic interaction in treating neuronal hyperexcitability disorder, especially in metabolic disorders that disrupt K_{ATP} activity. The mechanisms underlying excitotoxicity and seizure attenuation could differentiate PGB from diazoxide, and may explain the significant neuroprotective effects in the STZ+PGB group. Even so, the STZ+V group showed higher excitotoxicity than the NS+V group.

Previous reports [45] suggest that diazoxide may transiently elevate blood glucose levels, which can vary among individuals. We found no significant increment of blood glucose levels in control or diabetic rats after a single injection of diazoxide [12]. In the current study, neither acute nor chronic administration of PGB significantly altered blood glucose levels.

Our single-channel study that indicates PGB might involve an intracellular action. It has been proposed that PGB might involve both intracellular and extracellular sites of action, and a prolonged exposure to PGB produces delayed allosteric enhancement of voltage-activated potassium currents, which involves cAMP-
Pregabalin delays epileptogenesis in animal models of pilocarpine-induced epilepsy by protecting the entorhinal and piriform cortices [49]. In the present study, we observed decreased axonal sprouting and fewer seizures in the groups treated with PGB, which supports this notion. Recurrent excitation and the development of seizures have been associated with aberrant mossy fiber sprouting in the hippocampus [50]. Of interest, Ingram et al. [51] reported that inhibition of calcineurin or L-type calcium channels does not block mossy fiber sprouting in the model of pilocarpine-induced epilepsy, which suggests that the standard mechanism used by PGB to modulate high voltage-activated calcium channels has a limited effect on abnormal axonal sprouting. Furthermore, it is known that increased excitability in CA3 pyramidal neurons increases the probability of burst activity and leads to abnormal CA1 synchronization [52]. Although the histopathological findings showed marked cell loss at CA3 in the present study, the cEPSC evaluation at CA1 suggested that functionally altered excitability involves both the CA3-CA1 circuit and PGB’s integral effects on the CA3-CA1 network.

It is also interesting to know that PGB is the mainstay treatment for diabetic neuropathic pain. In neuropathic pain, an abnormal neuronal sprouting “wind-up” underlies the increased responsiveness to noxious stimuli and central sensitization. Zoga et al. [53] and Sarantopoulos et al. [54] described the down-regulation of K<sub>ATP</sub> in peripheral nerve injury, and Santos et al. [55] reported involvement of glibenclamide-sensitive K<sub>ATP</sub> in hyperalgesia and neuropathic pain. Given this understanding of the shared mechanism between epileptogenesis and neuropathic pain, as well as the specific role of K<sub>ATP</sub> in diabetes, the direct effects of K<sub>ATP</sub> opening by PGB on chronic axonal sprouting and epileptogenesis necessitate further investigations.

In addition to epilepsy and neuropathic pain, Yoon et al. [56] showed that PGB improved ischemic stroke outcome by suppressing calcium-mediated proteolysis in a mouse model. Whether this protective effect is partially related to K<sub>ATP</sub> opening, as was demonstrated previously in a hypoxia model [39], is worth attention. In an animal model of Alzheimer’s disease [57], long-term diazoxide treatment improved performance in a learning and memory test and reduced anxiety levels. Our study supports K<sub>ATP</sub>’s role in treating the hyperexcitability disorders, especially in diabetic hyperglycemia.

In conclusion, our study indicates that in diabetic hyperglycemia with seizures, PGB protects against seizures and neuronal excitotoxicity and is potentially antiepileptogenic. This study contributes to our understanding of a clinically applicable algorithm for treating patients with epilepsy and comorbid metabolic disorders.

Acknowledgments
A part of this manuscript was presented at the Taiwan Epilepsy Society Annual Meeting, 2010. The authors acknowledge Jen-Nan Wu, who assisted in cell preparations and animal experiments used in this study.

Author Contributions
Conceived and designed the experiments: CWH MCL JTC. Performed the experiments: CWH MCL. Analyzed the data: JTC JJT CCH SNW. Contributed reagents/materials/analysis tools: CWH SNW. Wrote the paper: CWH SNW.

References
1. Ford ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28: 2745–2749.
2. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T (2010) Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol 61: 509–521.
3. Singh BM, Strobool RJ (1989) Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients. Ann Neurol 8: 155–160.
4. Huang CW, Tsai JJ, Ou HY, Wang ST, Cheng JT, et al. (2008) Diabetic hyperglycemia is associated with the severity of epileptic seizures in adults. Epilepsy Res 79: 71–77.
5. Lee EB, Warnam G, Dhir R, Ahima RS (2011) Metabolic dysfunction associated with adiponectin deficiency enhances kainic acid-induced seizure severity. J Neurosci 31: 14361–14366.
6. Huang CW, Cheng JT, Tsai JJ, Wu SN, Huang CC (2009) Diabetes aggravates epileptic seizures and status epilepticus-induced hippocampal damage. Neurosci Res 15: 71–81.
7. Huang CW, Huang CC, Cheng JT, Tsai JJ, Wu SN (2007) Glucose and hippocampal neuronal excitability: role of ATP-sensitive potassium channels. J Neurosci Res 85: 1460–1477.
8. Shyng S, Nichols CG (1997) Octameric stoichiometry of the KATP channel complex. J Gen Physiol 110: 635–664.
9. Dunn-Meynell AA, Ravson NE, Levin BE (1998) Distribution and phenotype of neurons containing the ATP-sensitive K<sup>-</sup> channel in rat brain. Brain Res 814: 41–54.
10. Zawar C, Plant TD, Schirra C, Konnerth A, Neumcke B (1999) Cell-type specific expression of ATP-sensitive potassium channels in the rat hippocampus. J Physiol 514: 327–341.
11. Betourne A, Berthollet AM, Lahroue E, Halley H, Sun HS, et al. (2009) Involvement of hippocampal CA3 K<sub>ATP</sub> channels in contextual memory. Neuropharmacology 56: 613–625.
12. Huang CW, Wu SN, Cheng JT, Tsai JJ, Huang CC (2010) Diazoxide reduces status epilepticus neuron damage in diabetes. Neurotox Res 17: 305–316.
13. Ferrier RE (1992) Drug-induced diabetes. Bailleures Clin Endocrinol Meta 6: 849–866.
14. Levin BE, Dunn-Meynell AA (1998) Effect of streptozotocin-induced diabetes on rat brain sulfonylurea binding sites. Brain Res Bull 46: 513–518.
15. Tomson T, Almas M, Giordano S, Cabrera J (2011) The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: a post hoc analysis of combined clinical trials. Epilepsy Res 96: 64–73.
16. Bider M, Johannessen SK, Kupferberg HJ, Levy RH, Perucca E, et al. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference \textit{EILAT VII}. Epilepsy Res 61: 1–48.
17. Schmitz B, Montours G, Schuable B, Caleos S (2010) Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control. Epilepsy 51: 2231–2240.
18. Lyddard RB, Räckel K, Herman B, Felmer DE (2010) Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 13: 229–241.
19. Quintero JE, Dooley DJ, Pomerleau F, Huetl P, Gerhardt GA (2011) Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca<sup>2+</sup>-1 subunit. J Pharmacol Exp Ther 338: 240–245.
20. Huang CW, Huang CC, Wu SN (2006) The opening of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived HI9-7 cells. Epilepsia 47: 720–726.
21. Chiang YC, Chiang HY, Lin TK, Chang CC, La CH, et al. (2012) Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 53: 120–126.
22. Rosenstock J, Tuchman M, LaMorieux L, Sharma U (2004) Pregabalin in the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110: 620–635.
23. Oomen A (1991) Carbamazepine-induced Diabetes mellitus. Cent Afr J Med 37: 96–98.
24. Qi H, Newman GC (1996) Phenoythoin-induced hyperglycaemia may confound rat cerebroprotection models. Clin Exp Pharmacol Physiol 23: 893–897.
25. Rosenstock J, Hollander P, Gadele KM, Sun X, Strauss R, et al. (2007) A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 30: 1480–1486.
26. Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, Karall D, Schoenherr E, et al. (2008) Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 80: 142–149.
27. Pathak HR, Wulfsen I, Terunuma M, Carlson GC, Huang FC, et al. (2000) Expression of mRNA for voltage-dependent and inward-rectifying K channels in GH3/B6 cells and rat pituitary. J Neuroendocrinol 12: 263–272.
28. Huang CW, Chow JC, Tsai JJ, Wu SN (2012) Characterizing the effects of Eugenol on neuronal current properties and hyperexcitability. Psychopharmacology (Berl) 221: 575–587.
29. Mello LE, Cavaleiro EA, Tan AM, Kupfer VR, Pretoius JK, et al. (1993) Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: cell loss and mossy fiber sprouting. Epilepsia 34: 985–995.
30. Chang YC, Huang AM, Kuo YM, Wang ST, Chang YY, et al. (2003) Febrile seizures impair memory and cAMP response-element binding protein activation. Ann Neurol 54: 706–718.
31. Pitkanen A, Schwartzkroin PA, Moshe SL (2006) Models of seizures and epilepsy. Elsevier Academic Press, Burlington.
32. Holmes GL, Ben-Ari Y (1998) Seizures in the developing brain: perhaps not so benign after all. Neuro 21: 1231–1234.
33. Morrione A, Romano G, Navarro M, Reiss K, Valentinis B, et al. (2000) Insulin-like growth factor I receptor signaling in differentiation of neuronal H1-9 cells. Cancer Res 60: 2548–2572.
34. Zhang H, Verkman AS (2008) Aquaporin-4 independent Kir6.1 K* channel function in brain glial cells. Mol Cell Neurosci 37: 1–10.
35. Zhao M, Yang H, Jiang X, Zhou W, Zhu B, et al. (2008) Lipofectamine RNAiMAX: an efficient siRNA transfection reagent in human embryonic stem cell. Mol Biotechnol 40: 19–26.
36. Wulfsen I, Hauber HP, Schiemann D, Bauer CK, Schwarz JR (2000) Disrupted dentate granule cell chloride regulation enhances synaptic excitation during development of temporal lobe epilepsy. J Neurosci 27: 14012–14022.
37. Huang GW, Chow JC, Tsai JJ, Wu SN (2012) Characterizing the effects of Eugenol on neuronal current properties and hyperexcitability. Psychopharmacology (Berl) 221: 575–587.
38. Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, Karall D, Schoenherr E, et al. (2008) Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 80: 142–149.
39. Pathak HR, Wulfsen I, Terunuma M, Carlson GC, Huang FC, et al. (2000) Expression of mRNA for voltage-dependent and inward-rectifying K channels in GH3/B6 cells and rat pituitary. J Neuroendocrinol 12: 263–272.
40. Soundarapandian MM, Wu D, Zhong X, Petralia RS, Peng L, et al. (2007) Expression of functional Kir6.1 channels regulates glutamate release at CA3 synapses in generation of epileptic form of seizures. J Neurochem 103: 1982–1989.
41. Curia G, Lougo D, Biajini G, Jones RS, Avoli M (2008) The pilocarpine model of temporal lobe epilepsy. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods 172: 143–157.
42. Tay AS, Hu LF, Lu M, Wong PT, Bian JS (2010) Hydrogen sulfide protects neurons against hypoxic injury via stimulation of ATP-sensitive potassium channel/protein kinase C/extracellular signal-regulated kinase/heat shock protein 90 pathway. Neuroscience 167: 277–286.
43. Bancila V, Nikonenko I, Dunant Y, Bloc A (2004) Zn+ ions inhibit glutamate release via activation of pre-synaptic K channels and reduces ischemic damage in rat hippocampus. J Neurochem 90: 1243–1250.
44. Taylor CP, Angelotti T, Fauman E (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel alpha-2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73: 157–150.
45. Hennigsen L, Johansen K (1976) Growth hormone secretion and diazoxide induced hyperglycemia. Horm Metab Res 10: 563–566.
46. McCormand D, Evans RM, Barkworth L, Martin DJ, Scott RH (2004) A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC Pharmacol 4: 1–14.
47. Eckstein-Ludwig U, Fei J, Schwarz W (1999) Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br J Pharmacol 128: 92–102.
48. Ryu JH, Lee PB, Kim JH, Do SH, Kim CS (2012) Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anaesth 109: 234–239.
49. Andre V, Dubé C, François J, Leroy C, Ragoulot MIA, et al. (2007) Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia 48: e1–e7.
50. Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, et al. (2007) Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol Pathol 35: 984–999.
51. Ingram EA, Toyoda I, Wen X, Buckmaster PS (2009) Prolonged infusion of inhibitors of calcium entry or L-type calcium channels does not block mossy fiber sprouting in a model of temporal lobe epilepsy. Epilepsia 50: 56–64.
52. Queiroz CM, Mello LE (2007) Synthetic plasticity of the CA3 commissural projection in epileptic rats: an in vivo electrophysiological study. Eur J Neurosci 25: 3071–3079.
53. Zoga V, Kawamoto T, Liang MY, Bienengraeber M, Weihrauch D, et al. (2010) KATP channel subunits in rat dorsal root ganglia: alterations by painful axotomy. Mol Pain 6: 6.
54. Sarantopoulos C, McCullum B, Sapunar D, Kwok WM, Hogan Q (2003) ATP-sensitive potassium channels in rat primary afferent neurones: the effect of neuropathic injury and gabapentin. Neurosci Lett 343: 185–189.
55. Santos FA, Jeferson FA, Santos CC, Silveira ER, Rao VS (2009) Antinociceptive effect of azelastine hydrochloride in the formalin test. Toxicol Res 41: 624–629.
56. Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, et al. (2010) The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer’s disease. J Alzheimers Dis 22: 443–457.

Pregabalin Attenuates Excitotoxicity in Diabetes